Dupixent

Regeneron and Sanofi announced positive Phase 4 trial results for Dupixent in treating moderate-to-severe atopic dermatitis in adults and adolescents with skin of color. The DISCOVER trial, involving 120 patients, showed significant improvements in disease severity, itch reduction, and post-inflammatory hyperpigmentation. The safety profile aligned with previous findings. This marks a significant advancement in treating this often-underserved population.